TVRD vs UNCY

Tvardi Therapeutics, Inc. vs Unicycive Therapeutics, Inc. — Valuation Comparison 2026

TVRD

Biotechnology
Tvardi Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
32
LOW
Price
$3.49
Last close
Models
7/13
Active
VS

UNCY

Biotechnology
Unicycive Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
36
LOW
Price
$7.02
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType TVRD Fair ValueTVRD Upside UNCY Fair ValueUNCY Upside
Bayesian DCF Intrinsic $2.17 -28.9% $2.65 -62.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $0.56 -92.7%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.04 -3.1% $1.54 -78.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TVRD vs UNCY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TVRD vs UNCY — Which Stock Is More Undervalued?

UNCY scores higher with a 4.3/10 quality rating vs TVRD's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tvardi Therapeutics, Inc. (TVRD) and Unicycive Therapeutics, Inc. (UNCY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TVRD currently trades at $3.49 with a QOC of 4.1/10, while UNCY trades at $7.02 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).